Amy Dyken, controller at Skysong Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Skysong's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017 SKYSONG PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 996 convertible bonds payable 10% bonds payable $1,010,000 5,090,000 6,060,000 $12,160,000 Total long-term debt Shareholders equity Preferred stock, 6% cumulative, $50 par value, 93,000 shares authorized, 23,250 shares issued and outstanding $1,162,500 990,000 3,930,000 6,020,000 $12,102,500 Common stock, $1 par, 9,900,000 shares authorized, 990,000 shares issued and outstanding Additional paid-in capital Retained earnings Total shareholders' equity The following transactions have also occurred at Skysong. 1. Options were granted on July 1, 2016, to purchase 190,000 shares at $16 per share. Although no options were exercised during fiscal year 2017, the average price per common share during fiscal year 2017 was $20 per share. 2. Each bond was issued at face value. The 9% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2016. 3. The preferred stock was issued in 2016 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2017 5. The 990,000 shares of common stock were outstanding for the entire 2017 fiscal yean 6. Net income for fiscal year 2017 was $1,520,000, and the average income tax rate is 40%. For the fiscal year ended June 30, 2017, calculate the following for Skysong Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.) (a) Basic eanings per share Basic earnings per share (b) Diluted earnings per share. Diluted earnings per share